First-in-Class Composite Angiotensin Receptor–Neprilysin Inhibitors (ARNI) in Practice

Volume: 102, Issue: 2, Pages: 265 - 268
Published: Aug 1, 2017
Abstract
Sacubitril/valsartan, a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) inhibits angiotensin II and neprilysin, enhancing circulating vasoactive peptides. It is recommended in heart failure with reduced ejection fraction (HFrEF) as a result of the PARADIGM-HF trial.1 This review discusses the rationale for neprilysin inhibition, data supporting efficacy, and practical tips for patient selection and...
Paper Details
Title
First-in-Class Composite Angiotensin Receptor–Neprilysin Inhibitors (ARNI) in Practice
Published Date
Aug 1, 2017
Volume
102
Issue
2
Pages
265 - 268
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.